Connect with us

Advocacy

Stop censoring CBD: New cannabis coalition aims to prevent censorship

A US campaign has been launched with the aim of preventing the censorship of CBD products. They are aiming for 10,000 signatures by the end of August.

Published

on

Censoring CBD: The logo of a new campaign aimed at preventing censorship of CBD companies

A campaign from a new cannabis industry coalition has been launched with the aim of preventing censorship of CBD products.

The Cellular Telecommunications and Internet Association (CTIA), a non-profit trade organisation that monitors US content relating to sex, hate, alcohol, firearms and tobacco (collectively known as SHAFT), recently added CBD to its list.

As a result, CBD companies are no longer permitted to use SMS messaging for marketing purposes. In response to this decision, a number of cannabis companies have launched the campaign Stop Censoring CBD, led by CBD brand Prima.

The movement has built a group of advocates, who are lobbying for the unlocking of the industry via a Change.org petition, aiming for 10,000 signatures by August.

The founding members of the movement include top CBD brands such as Plant People, Svn Space, Foria Wellness and Papa and Barkley among many others. Other brands include Onda Wellness, oHHo and Plant Society.

Censoring CBD: A list of the CBD brands involved in a new anti-censorship campaign

Image credits: Prima CBD #FreeCBD campaign

Censoring CBD through Text marketing

Text messaging is a form of direct communication for many CBD wellness companies to help educate consumers about their products, and the benefits of CBD generally; as well as managing customer services.

Upon completion of the petition, Stop Censoring CBD hopes it will encourage lawmakers to co-sponsor and pass the Hemp Access and Consumer Safety Act (S. 1698). This, it says, will establish legal and regulatory pathways for the nationwide sale of hemp-derived extract products.

In 2018, hemp was removed from the US federal government’s list of controlled substances. But clear FDA guidelines or policies regarding hemp-derived CBD, have yet to be published. The coalition also plans to put pressure on the FDA to move forward with regulatory actions that would separate hemp-derived CBD from other CBD.

READ MORE  BMJ publishes first case study of medical cannabis for chronic pain

It believes this will collectively create a framework for companies to ensure compliance and protect consumers with clear guidelines and standards for safety, labelling, potency, growing practices, manufacturing and communications for all products.

Read more: Irish campaigner responds to doctors proposal to shun MCAP programme

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Advocacy

Europe’s largest patient registry expands to offer more affordable access

The Sapphire Access Scheme has expanded to reach an additional 2,000 patients across the UK.

Published

on

Sapphire Medical Clinic: A doctor writing a medical prescription

Published patient data within The UK Medical Cannabis Registry suggests positive changes were observed in pain, anxiety and sleep-specific health-related outcomes.

The Sapphire Access Scheme allows patients to be included for free in the UK Medical Cannabis Registry (“The Registry”) and receive £50 appointments. The Registry is the first such database in the UK and was set up by Sapphire Medical Clinics (“Sapphire Clinics”), the UK’s first and highest-rated medical cannabis clinic.

It includes over 3,000 patients as part of the Sapphire Access Scheme and an analysis of the clinical outcomes measured in patients in the UK with chronic pain has been published in the international peer-reviewed journal ‘Expert Review of Clinical Pharmacology’.

The results from this study of 190 patients suggest that treatment with cannabis-based medicinal products (CBMPs) has an acceptable safety profile and is associated with improved pain-specific outcomes and health-related quality of life at 1, 3 and 6 months following treatment initiation. Adverse events (side effects) were reported by 18.7 per cent of patients suggesting a favourable tolerance relative to medications, such as opioids, that are prescribed more frequently.

Sapphire Access Scheme

To mark the success of the Real-World Evidence published internationally, the Sapphire Access Scheme has expanded to an additional 2,000 patients across the UK. Eligible patients will benefit from significant cost savings, including initial appointments priced at £50, in recognition of their contribution to the groundbreaking initiative that is successful in rapidly expanding the evidence base for medical cannabis.

The Registry is the largest European database of its kind and captures patient outcomes as well as safety profiles of medical cannabis. Medical cannabis can be prescribed by specialist doctors when conventional therapy has not provided adequate symptom relief for conditions such as pain, anxiety, and insomnia. All patients enrolled in the Registry have access to individualised health metrics and can freely monitor treatment progress over time.

READ MORE  UK CBD firm becomes first to work with local authorities

Dr Simon Erridge, head of research and access at Sapphire Clinics commented “As a multi-award-winning medical cannabis clinic, we are delighted to further improve access to this treatment option where other therapies haven’t worked. By collecting patient-reported outcomes and producing peer-reviewed analysis in return, together we inform the wider evidence base of the efficacy and safety of medical cannabis, which is essential for ensuring the correct patients are able to access treatment.”

Sapphire Medical Clinics patient Jack Pierce, added: “I am eligible for treatment as I previously had tried standard therapies for a range of multiple mental health conditions, consisting of Anxiety, Depression, ASD (Autism) and ADHD. The Sapphire Access Scheme has allowed me to see a specialist consultant and be prescribed medicines based on my individual needs. I have access to all health metrics such as sleep scores, daily activities and quality of life for free so that I benefit from this scheme as well as contribute to the evidence base which is accelerating in the UK, three years since the change in the law.”

Who is eligible for £50 appointments?

All patients eligible for treatment with medical cannabis can enrol on the Sapphire Access Scheme and access the £50 appointments. Medical cannabis can be considered when first-line treatments have not achieved adequate benefit or produced side effects. Find out more and complete the eligibility assessment online: https://www.sapphireclinics.com/eligibility-assessment/

Sapphire Access Scheme Pricing

£50 – Initial Appointment
£50 – Monthly one follow-up appointment
£50 – Quarterly check-up appointment
£50 – Transfer patient appointment
£0 – No repeat prescription fees

READ MORE  Pain tolerance among cannabis users investigated

Find out more about the Sapphire Access Scheme and pricing: https://www.sapphireclinics.com/pricing/ 

Sapphire medical clinic: A banner stating this is collaborative content

Continue Reading

Advocacy

CBDSQ share how they put people first and profits last

Join CBDSQ in their green revolution and together help to change the world

Published

on

CBDSQ explain how their CBD helps to give back by planting trees to fight climate change and they donate to families in need

We at CBDSQ harvest from organically grown, sun fed hemp plants grown in Spain and it is extracted in the UK to the highest possible standards.

We believe that our CBD products are amongst the best in the UK.

When it comes to quality we do not compromise. We believe in putting people first and profits last because helping people is our mission.

CBDSQ tree promise

With every purchase with us, we promise to plant trees all around the world to help protect this planet for many generations to come. We also participate in charity work within our local area to further our impact on society and indeed, the world.

Founded in 2020 at the height of the pandemic, we set out with a clear objective, to destigmatise cannabis and indeed CBD.

Having used CBD for many years we knew first-hand just how powerful the hemp plant can be. From its anti-inflammatory properties to its calming effect. CBD really can be beneficial for anybody so we set out to make it happen.

We only use natural ingredients in our products, No unwanted or unnecessary chemicals or ingredients are added, Just straightforward honest ingredients and products.

CBDSQ CBD

At heart, our business is all about helping people become the best they can be but we don’t just draw the line at people. We have also taken steps to protect our planet from further damage from climate change, So we have teamed up with ECOLOGI.

READ MORE  Hollywood legend Tommy Chong launches CBD line

For every order you place with us we promise to plant trees all around the world in a bid to offset the damage done by climate change.

Not only this but over the Christmas period, a percentage of our profits will go to help children in need this year. We will provide families less fortunate than ours. This means clothing, presents, food and of course our CBD magic will be spread too.

Join us in our green revolution and together we can change the world!

Visit CBDSQ

CBDSQ: A banner advertising sponsored content

Continue Reading

Advocacy

Medical cannabis campaigners share anger at reading of new bill in parliament

“This is simply unforgivable. What a smack in the face this is for our families and at Christmas too. So once again, we get warm words, but no solution.”

Published

on

Parliament buildings in the UK

Campaigners have reacted in anger, despair and frustration to the second reading of a bill in parliament designed to increase access to medical cannabis.

The families have reacted in a mixture of anger, frustration and despair at the use of what they feel are ‘cynical parliamentary tactics’ to stop the progress of NHS access.

Politicians from different parties shared in parliament their concerns and the stories of medical cannabis patients in their constituencies. Some of the issues raised included the cost of medical cannabis, the lack of doctors who can prescribe, no support for patients and families. The politicians shared the health benefits experienced by the patients themselves.

Response to parliamentary reading

Speaking with Cannabis Health News, campaigner and mother of Alfie Dingley, Hannah Deacon commented:

“It is terribly depressing that even though the government is aware of all the issues that are deeply affecting patients, where they have no choice but be faced with large bills for cannabis medication which keeps them or their children well, they still do not give the time or thought to how they could help improve things for these very chronically ill patients.

“This bill went some way to try to improve access to medical cannabis in the U.K. and we thank Jeff Smith MP for bud continued support. Why does the government blatantly continue to prolong the suffering of so many.”

Medical cannabis campaign group, End Our Pain highlighted that ‘it seems that the government is refusing to support and will instead ‘talk out’ the bill.”

Peter Carroll, director of End Our Pain said: “This Bill may not have been perfect. But it is a genuine attempt to unlock a problem that is causing unbearable anxiety and stress to some of the most vulnerable families in the country. After the law change of 1 November 2018, which saw access under prescriptions legalised, the hopes of these families have been raised and subsequently dashed. They have been passed from pillar to post and systematically let down.

READ MORE  Hollywood legend Tommy Chong launches CBD line

“A succession of Ministers have expressed their interest and concern. There have been reviews, debates and motions. But these families continue to suffer. They need help right now. Our question to the Government and Ministers is this – if this Bill is not the answer, what is?

“To simply talk this Bill out without offering an alternative solution is cynical and cruel. This is a solvable problem. At the very least, these families need some sort of emergency compassionate fund to help pay for the private prescriptions until the underlying problems with NHS prescribing can be addressed.”

Joanne Griffiths, whose story was shared in parliament by MP Katherine Fletcher, said: “This is simply unforgivable. What a smack in the face this is for our families and at Christmas too. So once again, we get warm words, but no solution.

“Every month is hard to bear for us as we fight to find the money to pay for this medicine. The sums of money to solve this are tiny. All that is needed is the political will to solve it.”

Katherine Fletcher raised in parliament how Joanne’s son Ben is still denied an NHS prescription leaving the family to fundraise to meet the costs of his private medication. She highlighted that they were ‘on the verge of being broken’ due to the financial stress along with COVID and trying to run a business at the same time.

READ MORE  ‘If CBD is good enough for my dogs, it’s good enough for me’

Speaking with Cannabis Health News, Joanne explained her disappointment at the lack of contact she has had with the MP despite what was said in parliament.

“I feel that my seriously disabled son and myself were used to talk out a Bill that may help him and others like him.

Our local MP Katherine Fletcher was asked by Seema Kennedy her conservative predecessor to help our son and to date since 2019 we have had a 15-minute conversation in a pub and one letter regarding Brexit, she has ignored us constantly until this Bill. I really thought she wanted to help us when she said she would attend, but she has completely let us down again and followed the party line.

If Katherine has admiration for me as she stated, then she would fight for a compassionate fund for children that have been deemed as being exceptional by specialists and now receive the cannabis medications keeping them well and who have had an exceptional response and need where all else has failed.”

Parliamentary debates

The bill, proposed by Jeff Smith, Labour MP for Manchester Withington in June 2021, aims to remove some of the barriers by allowing the expansion of GPs ability to prescribe unlicensed cannabis medical products.

The GPs would be on a register maintained by the General Medical Council.  GPs in the UK can prescribe as part of a shared care arrangement, under the direction of a specialist consultant.

It would also aim to establish a Commission for the assessment of cannabis-based medicinal products.

Speaking in Parliament today, Jeff Smith highlighted that there are many patients who would benefit from the bill. He also raised the issue of forcing parents to fundraise for their medication. He raised the issues faced by different patients with epilepsy and Ehlers-Danlos syndrome.

READ MORE  “Our son’s life is in danger” - mum’s plea as son’s medical cannabis prescription runs out

“Ministers appreciate the problem and want to try and find a way around it. The problem is that medical cannabis based medical products are a very helpful and effective treatment for a number of medical conditions. But significant numbers of people who would benefit from being prescribed medical cannabis on the NHS aren’t able to get the prescriptions that they need.

So when I was drawn for the private member’s bill, I wanted to try and find a legislative way to address this problem,” he said.

He added: “My modest proposals today try to find a way to help overcome the barriers. It’s not a magic bullet and it won’t resolve all problems, but it might in due course help to help some patients get the medicine that they need.”

Parliament: A banner advert for cannabis health news

Continue Reading

Trending